Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

A survey of ENT clinicians reveals variability in managing chronic rhinosinusitis with nasal polyps, including steroid ...

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo ...

Although patients with asthma commonly have coexisting chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP), research on the effect of biologics has focused on ...

GSK: Depemokimab Shows Significant Improvements For CRSwNP Patients In Phase III Trials March 03, 2025 — 02:45 am EST Written by RTTNews.com for RTTNews -> ...

Dupixent ® (dupilumab) sBLA accepted for FDA Priority Review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis (CRSwNP). News release. Regeneron Pharmaceuticals, Inc ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis (EoE ...